Literature DB >> 30663609

Association between pathological and MRI findings in multiple sclerosis.

Massimo Filippi1, Wolfgang Brück2, Declan Chard3, Franz Fazekas4, Jeroen J G Geurts5, Christian Enzinger4, Simon Hametner2, Tanja Kuhlmann6, Paolo Preziosa2, Àlex Rovira7, Klaus Schmierer8, Christine Stadelmann2, Maria A Rocca9.   

Abstract

Pathological evaluation is the gold standard for identifying processes related to multiple sclerosis that explain disease manifestations, and for guiding the development of new treatments. However, there are limitations to the techniques used, including the small number of donors available, samples often representing uncommon cases, and impossibility of follow-up. Correlative studies have demonstrated that MRI is sensitive to the different pathological substrates of multiple sclerosis (inflammation, demyelination, and neuro-axonal loss). The role of MRI in evaluating other pathological processes, such as leptomeningeal involvement, central vein and rim of lesions, microstructural abnormalities, iron accumulation, and recovery mechanisms, has been investigated. Although techniques used for quantifying pathological processes in different regions of the CNS have advanced diagnosis and monitoring of disease course and treatment of multiple sclerosis, new perspectives and questions have emerged, including how different pathological processes interact over the disease course and when remyelination might occur. Addressing these questions will require longitudinal studies using MRI in large cohorts of patients with different phenotypes.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2019        PMID: 30663609     DOI: 10.1016/S1474-4422(18)30451-4

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  41 in total

1.  Effects of fingolimod treatments on alanine transaminase and aspartate transaminase levels in patients with multiple sclerosis.

Authors:  Saeid Sadeghi Joni; Masoumeh Cheshmavar; Pouria Shoureshi; Zohreh Zamani; Niusha Taoosi; Morteza Akbari; Mahdieh Afzali
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2020-06-15

2.  The novel small-molecule TPN10456 inhibits Th17 cell differentiation and protects against experimental autoimmune encephalomyelitis.

Authors:  Cuixia Yang; Jie Lv; Xiangrui Jiang; Zhenglong Xiang; Ran Gong; Jiahua Xing; Guangyu Liu; Ling Xie; Kandireya Saimaier; Yan Zhang; Junjian Wang; Hu Shen; Juping Pan; Jingshan Shen; Changsheng Du
Journal:  Cell Mol Immunol       Date:  2020-10-27       Impact factor: 11.530

3.  Resting state network functional connectivity abnormalities in systemic lupus erythematosus: correlations with neuropsychiatric impairment.

Authors:  Raffaello Bonacchi; Maria A Rocca; Giuseppe A Ramirez; Enrica P Bozzolo; Valentina Canti; Paolo Preziosa; Paola Valsasina; Gianna C Riccitelli; Alessandro Meani; Lucia Moiola; Patrizia Rovere-Querini; Angelo A Manfredi; Massimo Filippi
Journal:  Mol Psychiatry       Date:  2020-10-13       Impact factor: 15.992

4.  Three-dimensional virtual histology of the cerebral cortex based on phase-contrast X-ray tomography.

Authors:  Marina Eckermann; Franziska van der Meer; Peter Cloetens; Torben Ruhwedel; Wiebke Möbius; Christine Stadelmann; Tim Salditt
Journal:  Biomed Opt Express       Date:  2021-11-15       Impact factor: 3.732

5.  The role of cerebellar damage in explaining disability and cognition in multiple sclerosis phenotypes: a multiparametric MRI study.

Authors:  Raffaello Bonacchi; Alessandro Meani; Elisabetta Pagani; Olga Marchesi; Massimo Filippi; Maria A Rocca
Journal:  J Neurol       Date:  2022-03-01       Impact factor: 4.849

6.  Evolution of acute "black hole" lesions in patients with relapsing-remitting multiple sclerosis.

Authors:  Dejan Kostic; Evica Dincic; Aleksandar Jovanovski; Smiljana Kostic; Nemanja Rancic; Biljana Georgievski-Brkic; Miroslav Misovic; Katarina Koprivsek
Journal:  Acta Neurol Belg       Date:  2022-04-09       Impact factor: 2.396

Review 7.  Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis.

Authors:  Heather Y F Yong; V Wee Yong
Journal:  Nat Rev Neurol       Date:  2021-11-03       Impact factor: 42.937

8.  Lesion features on magnetic resonance imaging discriminate multiple sclerosis patients.

Authors:  Sandra M Hurtado Rúa; Ulrike W Kaunzner; Sneha Pandya; Elizabeth Sweeney; Ceren Tozlu; Amy Kuceyeski; Thanh D Nguyen; Susan A Gauthier
Journal:  Eur J Neurol       Date:  2021-08-29       Impact factor: 6.089

Review 9.  New insights in the mechanisms of impaired redox signaling and its interplay with inflammation and immunity in multiple sclerosis.

Authors:  D Michaličková; M Šíma; O Slanař
Journal:  Physiol Res       Date:  2019-12-19       Impact factor: 1.881

10.  Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Xin Wu; Tao Xue; Zilan Wang; Zhouqing Chen; Xuwei Zhang; Wei Zhang; Zhong Wang
Journal:  Front Pharmacol       Date:  2021-05-17       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.